IncellDx’s Quantitative Immuno-Oncology Assay OncoTect iO Published in New Study
As Dr. Patterson explained, “We believe this objective quantitation of PD-L1 expression in tumor and immune cells in NSCLC will allow for better prediction of patient response to the new PD-1 immunotherapies within a work flow that is suited well for primary indications where the initial diagnosis may be made using several approaches to sampling the tumor. Further, the assay and sample preparation are automated allowing for same day turn around.”
The PD-L1 and PD-1 assay is the first release of IncellDx, Inc.’s newest family of single cell, multi-parametric molecular products called OncoTect® iO for immuno-oncology in a multitude of tissue types. The paper is now available online at http://link.springer.com/article/10.1007/s00262-016-1889-3.
About IncellDx Inc.
IncellDx, Inc. is a single cell diagnostics company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers. The Company develops products designed to address pressing unmet clinical needs in the advancement of cancer care in addition to its virology products.
For more information, please visit www.incelldx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005461/en/
Website: http://www.incelldx.com
Contact
IncellDx, Inc.
Chris Meda
+1-650-777-7630
This news is a press release provided by IncellDx, Inc..
-
2018년 1월 18일 13:40